Cantargia AB
STO:CANTA

Watchlist Manager
Cantargia AB Logo
Cantargia AB
STO:CANTA
Watchlist
Price: 1.812 SEK -2.42% Market Closed
Market Cap: 332.8m SEK
Have any thoughts about
Cantargia AB?
Write Note

Cantargia AB
Long-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cantargia AB
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Cantargia AB
STO:CANTA
Long-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Long-Term Investments
kr28.1m
CAGR 3-Years
796%
CAGR 5-Years
266%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Long-Term Investments
kr217k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Long-Term Investments
kr54m
CAGR 3-Years
20%
CAGR 5-Years
11%
CAGR 10-Years
24%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Long-Term Investments
kr175m
CAGR 3-Years
-3%
CAGR 5-Years
-17%
CAGR 10-Years
10%
BioArctic AB
STO:BIOA B
Long-Term Investments
kr1.6m
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
N/A
No Stocks Found

Cantargia AB
Glance View

Market Cap
332.8m SEK
Industry
Biotechnology

Cantargia AB is a holding company, which engages in the development of antibody-based cancer treatment. The company is headquartered in Lund, Skane. The company went IPO on 2015-03-17. The firm is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.

CANTA Intrinsic Value
1.024 SEK
Overvaluation 44%
Intrinsic Value
Price

See Also

Back to Top